Arrowhead Pharmaceuticals Develops Novel Plozasiran
Arrowhead Pharmaceuticals has developed plozasiran (formerly ARO-APOC3), a novel investigational therapy designed to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
FCS is a rare genetic condition characterised by extremely high triglyceride levels, which can lead to life-threatening pancreatitis and other serious health issues. Current treatment options for FCS are limited, making plozasiran a potentially groundbreaking therapy.
Plozasiran is a pioneering RNA interference (RNAi) therapy designed to target apolipoprotein C-III (APOC3), a protein that plays a crucial role in triglyceride metabolism. APOC3 inhibits the breakdown of triglyceride-rich lipoproteins (TRLs) and slows their removal from the bloodstream. By lowering APOC3 levels, plozasiran seeks to reduce triglycerides and help restore lipid balance.
Clinical trials have shown promising results for plozasiran, with significant reductions in triglycerides and atherogenic lipoproteins in patients with FCS, severe hypertriglyceridemia (SHTG), and mixed hyperlipidaemia.
The therapy has also demonstrated a favourable safety profile, with reported adverse events largely reflecting the existing comorbidities in study populations.
Given its efficacy and safety in clinical studies, plozasiran holds strong potential for further development and commercialisation in treating not only FCS but also other lipid disorders.
The U.S. FDA has granted breakthrough therapy designation to investigational plozasiran as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS).
